Fusion Antibodies PLC Block admission six monthly return
02 Aprile 2024 - 3:34PM
RNS Regulatory News
RNS Number : 0066J
Fusion Antibodies PLC
02 April 2024
2 April 2024
Fusion Antibodies
plc
("Fusion"
or the "Company")
Block admission six monthly
return
Fusion Antibodies plc (AIM: FAB), specialists
in pre-clinical antibody discovery, engineering and supply for both
therapeutic drug and diagnostic applications, announces the following information in connection with its
block admission pursuant to AIM Rule 29 and Schedule Six of the AIM
Rules for Companies.
|
Name of company:
|
Fusion Antibodies plc
|
|
Name of scheme:
|
Historic options, EMI and Unapproved
Employee Share Option Scheme, as announced on 27 September
2021
|
|
Period of return:
|
From 2 October 2023 to 1 April
2024
|
|
Number and class of securities not
issued under the scheme at the beginning of the period:
|
293,750 ordinary shares of 4 pence
each in the Company ("Ordinary Shares")
|
|
Number of securities issued under the
scheme during the period:
|
Nil
|
|
Number of options under the scheme
that have lapsed during the period:
|
Options over 255,000 Ordinary
Shares
|
|
Balance under the scheme of
securities not yet issued at the end of the period:
|
38,750 Ordinary Shares
|
|
Number and class of securities
originally admitted and the date of admission:
|
917,083 Ordinary Shares on 27
September 2021
|
|
Contact name and telephone
number:
|
Stephen Smyth, Interim CFO via
Walbrook PR
+44 (0)20 7933 8780
|
Enquiries:
|
Fusion
Antibodies plc
|
www.fusionantibodies.com
|
|
Adrian Kinkaid, Chief Executive
Officer
Stephen Smyth, Chief Financial
Officer
|
Via Walbrook PR
|
|
|
|
|
Allenby
Capital Limited
|
Tel: +44 (0)20 3328 5656
|
|
James Reeve/Vivek Bhardwaj (Corporate
Finance)
Tony Quirke/Joscelin Pinnington (Sales and
Corporate Broking)
|
|
|
|
|
|
|
|
|
Shard Capital
Partners LLP
|
|
|
Damon Heath (Joint Broker)
|
Tel: +44 (0)207 186 9952
|
|
|
|
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933 8780
or fusion@walbrookpr.com
|
|
Anna Dunphy
|
Mob: +44 (0)7876 741 001
|
About Fusion
Antibodies plc
Fusion is a Belfast based contract research
organisation ("CRO") providing a range of antibody engineering
services for the development of antibodies for both therapeutic
drug and diagnostic applications.
The Company's ordinary shares were admitted to
trading on AIM on 18 December 2017. Fusion provides a broad range
of services in antibody generation, development, production,
characterisation and optimisation. These services include antigen
expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary
CDRx TM platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin
out from Queen's University Belfast. The Company's mission is to
enable pharmaceutical and diagnostic companies to develop
innovative products in a timely and cost-effective manner for the
benefit of the global healthcare industry. Fusion Antibodies
provides a broad range of services in antibody generation,
development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is based on
combining the latest technological advances with cutting edge
science to deliver new platforms that will enable Pharma and
Biotech companies get to the clinic faster, with the optimal drug
candidate and ultimately speed up the drug development
process.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLRUUOORSOUSRAR
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Dic 2023 a Dic 2024
